AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 4 - (NewsRx.com & NewsRx.net) -- Malaria vaccines based on Plasmodium vivax Sal I strains show promise in animal models.
"We have previously demonstrated that mouse antisera against yeast-produced recombinant forms of the ookinete surface proteins of Plasmodium vivax (Pvs25 and Pvs28) blocks transmission of the homologous P. vivax (Sal I strain). In this study, we developed mouse and rabbit antisera against Pvs25 and Pvs28 and evaluated the efficacy of these vaccine candidates against natural isolates of P. vivax in Thailand," scientists writing in the American Journal of Tropical Medicine and Hygiene report.
"Although both Pvs25 and Pvs28 genes are polymorphic, sera from mice immunized using alum adjuvant completely inhibited oocyst development for most human isolates, whereas sera from rabbits immunized with either alum or Freund's adjuvant were partially inhibitory," stated Jetsumon Sattabongkot at the Armed Forces Research Institute of Medical Sciences in Thailand and collaborators in Japan and Thailand.
"All inhibition occurred in an antibody dose-dependent fashion. Data from this study clearly demonstrates that antibodies raised against Sal I-based vaccines overcome the genetic polymorphism of Pvs25 and Pvs28 ...